Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders

Previous research has shown the efficacy of CROCUVIS+® dietary supplement, based on saffron extract, in the proper functioning of visual health, for example, against the development of glaucoma. The main objective of this study is to evaluate the efficacy of CROCUVIS® in computer vision syndrome, sleep and mood disorders in a sample of university students who use digital devices.

Study Overview

• Status: Completed
• Conditions: Mood Disorders; Sleep Disorder; Computer Vision Syndrome
• Intervention / Treatment: Dietary supplement: Saffron extract (Crocus sativus); Dietary supplement: Placebo

• Study Type: Interventional
• Enrollment (Actual): 100
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Spain
  • Alicante
    • San Vicente Del Raspeig, Alicante, Spain, 03690
      • University of Alicante

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• CVS-Q© score ≥6.
• Age between 18 and 40 years (both inclusive).
• Exposure to digital devices 4 hours a day, at least five days a week or more and maintain the same level of exposure throughout the study period.

Exclusion Criteria:

• Monocular corrected distance visual acuity >0.0 LogMAR.
• Ocular pathology under treatment at the time of the study.
• Previous ocular surgery that could affect the tear film or the ocular surface.
• Ocular Surface Disease Index (OSDI) questionnaire score ≥13.
• Previous diagnosis or history of dry eye syndrome and/or blepharitis.
• Regular (daily) use of rigid or soft contact lenses ≥3 days a week.
• Regular use of any ocular lubricant.
• History of oral intake of dietary supplements, with or without herbal ingredients, intended to contribute, maintain or reduce the risk of suffering diseases related to visual function, mood or sleep within the four weeks before the study enrollment.

• Systemic disease:

  1. Uncontrolled hypertension (systolic/diastolic blood pressure >140/90 mmHg).
  2. Uncontrolled diabetes mellitus (fasting blood glucose level >180 mg/dL).
  3. Rheumatoid arthritis.
  4. Tumor disease.
  5. Active hepatitis (type B and C).
  6. Active infectious disease.
  7. Kidney disease that compromises diuresis.

• Current systemic treatment or in the last 3 months with drugs that may interfere with the results, for example:

  1. Opioids.
  2. Antipsychotics.
  3. Antibiotics (tetracyclines, sulfonamides)
  4. Antiarthritic drugs (hydroxychloroquine)
  5. Hypotensive drugs (beta-blockers)
  6. Anticoagulants (heparin, warfarin, or clopidogrel)
  7. Antidepressants (such as fluoxetine, among others)
  8. Hypnotics (eg, benzodiazepines)
• Habitual smoker and/or alcohol drinker. More than 3 cigarettes per day and/or more than 3 Standard Drink Units (SDU) per week, including weekends. SDU is defined as the consumption of 10 ml of alcohol.
• Regular job with rotating shifts including night shift in the last month (including weekends).
• Pregnancy or breastfeeding (also excludes recent pregnancy within the last 3 months) and women planning to become pregnant.
• Participation in another clinical trial in the last 3 months.
• Take any type of dietary supplements with botanical components in the last month.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Saffron extract (Crocus sativus); Daily intake of one tablet for 42 days.	Dietary supplement: Saffron extract (Crocus sativus); Daily intake of one tablet for 42 days.
Placebo Comparator: Placebo; Daily intake of one tablet for 42 days. This tablet is organoleptically indistinguishable from the experimental tablet.	Dietary supplement: Placebo; Daily intake of one tablet for 42 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline computer vision syndrome at 14, 28 and 42 days	Measured with the Computer Vision Syndrome Questionnaire (CVS-Q©). It evaluates the frequency and intensity with which 16 symptoms are perceived over the time of use of digital devices. The score ranges from 0 to 32; computer vision syndrome is considered ≥6. The higher score a subject gained, the worsen ocular condition he/she experienced.	0 (baseline), 14, 28 and 42 days
Change from baseline sleep disorders at 14, 28 and 42 days	Measured with the Insomnia Severity Index (ISI). It evaluates 7 items. The score ranges from 0 to 28 (worst). Each item is evaluated on a 5-point Likert scale (from 0 to 4). The final score is obtained from the sum of the responses of all items; insomnia is considered ≥8.	0 (baseline), 14, 28 and 42 days
Change from baseline mood at 14, 28 and 42 days	Measured with the Profile of Mood States (POMS). It evaluates 58 items that form 6 factors (tension, depression, anger, vigour, fatigue, and confusion). The score ranges from 68 to 300 (worst mood). Each item is evaluated with a 5-point Likert scale (from 0 to 4). The score of each factor is obtained from the sum of the responses of all the items that define it. Total Mood Disturbance = 100+ (Tension + Depression + Anger + Fatigue + Confusion) - Vigour	0 (baseline), 14, 28 and 42 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline quality of life related to health at 42 days	Measured with Short Form-36 survey (SF-36). It evaluates 36 items that form 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, mental health). The scores are weighted sums of the questions in each section. The score ranges from 0 to 100. Lower scores = more disability, higher scores = less disability.	0 (baseline) and 42 days
Satisfaction question	A single satisfaction question. Participants must respond by selecting a number from a Likert scale from 0 to 5.	Last visit (42 day)

Collaborators and Investigators

• Sponsor: University of Alicante
• Collaborators: Pharmactive Biotech Products S.L.U

Study record dates

Study Major Dates

• Study Start (Actual): October 21, 2022
• Primary Completion (Actual): December 27, 2022
• Study Completion (Actual): May 5, 2023

Study Registration Dates

• First Submitted: December 10, 2021
• First Submitted That Met QC Criteria: January 26, 2022
• First Posted (Actual): January 27, 2022

Study Record Updates

• Last Update Posted (Estimate): May 11, 2023
• Last Update Submitted That Met QC Criteria: May 10, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Pathologic Processes; Nervous System Diseases; Neurologic Manifestations; Syndrome; Disease; Sleep Wake Disorders; Mood Disorders
• Other Study ID Numbers: PHARMACTIVE-21TPA

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No